Tags : EMD Serono

Pharma

EMD Serono and Pfizer to Terminate P-III JAVELIN Head and

Shots: The P-III JAVELIN Head and Neck 100 study involve assessing of Bavencio (avelumab) + CRT followed by avelumab maintenance vs CRT alone in 697 patients with previously untreated LA SCCHN The companies have accepted DMC’s recommendation to terminate the P-III JAVELIN Head and Neck 100 study as it did not meet its 1EPs i.e. […]Read More